Lead Product(s): Orvepitant Maleate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GW823296X
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Columbus Venture Partners
Deal Size: $27.8 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 07, 2021
New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). The chronic cough can markedly reduce quality of life, is often refractory to medical therapy and there are no approved treatments for it.